Antibodies | Selected Papers on Autoimmune Diseases
We are pleased to highlight 15 notable papers on autoimmune diseases published in Antibodies (ISSN 2073-4468) in 2024 and 2025. We invite you to explore these contributions, which reflect recent advances and emerging directions in autoimmune diseases.
1. “Anti-Type I Interferon Autoantibodies in COVID-19 and Systemic Lupus Erythematosus: A Comparative Review”
by Xin Rong Lim, Ryan Xuan Wei Teo, Rae Yi Xin Par and Bernard Pui Lam Leung
Antibodies 2026, 15(3), 50; https://doi.org/10.3390/antib15030050
Available online: https://www.mdpi.com/2073-4468/15/3/50
2. “Non-COVID-19 Vaccinations and the Induction of Autoantibodies in Pemphigus Diseases: A Review of the Speculative Issue and Our Clinical-Laboratory Experience”
by Maksymilian Markwitz, Natalia Welc, Klementyna Kępińska, Monika Bowszyc-Dmochowska and Marian Dmochowski
Antibodies 2026, 15(2), 33; https://doi.org/10.3390/antib15020033
Available online: https://www.mdpi.com/2073-4468/15/2/33
3. “Evaluation of Anti-dsDNA Antibodies in Laboratory Practice: Management of Different Analytical Methods and Correlation with HEp-2 Immunofluorescence Patterns”
by Massimo Papale, Carmela Paolillo, Loredana Iafelice, Tiziana Trivisano, Giuseppe Stefano Netti, Elena Ranieri and Gaetano Corso
Antibodies 2026, 15(2), 23; https://doi.org/10.3390/antib15020023
Available online: https://www.mdpi.com/2073-4468/15/2/23
4. “Dermatomyositis with Anti-MDA5 Autoantibodies After SARS-CoV-2 mRNA Vaccination Treated with Tofacitinib: Integrating Literature Evidence and a Novel Observation”
by Maurizio Benucci, Elisa Cioffi, Francesca Li Gobbi, Emanuele Antonio Maria Cassarà, Riccardo Terenzi, Edda Russo, Valentina Grossi, Barbara Lari, Maria Infantino and Mariangela Manfredi
Antibodies 2026, 15(2), 24; https://doi.org/10.3390/antib15020024
Available online: https://www.mdpi.com/2073-4468/15/2/24
5. “C1q Is Recognized as a Soluble Autoantigen by Anti-C1q Antibodies of Patients with Systemic Lupus Erythematosus”
by Alexandra Anatolieva Atanasova, Ginka Ilieva Cholakova, Alexandra Panagiotis Kapogianni, Vancho Donev, Delina Ivanova, Anna Dimitrova Yordanova, Vanya Petkova Bogoeva and Ivanka Georgieva Tsacheva
Antibodies 2025, 14(4), 94; https://doi.org/10.3390/antib14040094
Available online: https://www.mdpi.com/2073-4468/14/4/94
6. “Monoclonal Antibodies and Small-Molecule Therapies for Lichen Planus: Targeted Immunomodulation and Emerging Evidence”
by Francois Rosset, Nadia Sciamarrelli, Luca Mastorino, Valentina Pala, Sara Boskovic, Eleonora Bongiovanni, Orsola Crespi, Yingying Liao, Simone Ribero and Pietro Quaglino
Antibodies 2025, 14(3), 79; https://doi.org/10.3390/antib14030079
Available online: https://www.mdpi.com/2073-4468/14/3/79
7. “Antibodies to Laminin β4 in Pemphigoid Diseases: Clinical–Laboratory Experience of a Single Central European Reference Centre”
by Maciej Marek Spałek, Magdalena Jałowska, Natalia Welc, Monika Bowszyc-Dmochowska, Takashi Hashimoto, Justyna Gornowicz-Porowska and Marian Dmochowski
Antibodies 2025, 14(3), 66; https://doi.org/10.3390/antib14030066
Available online: https://www.mdpi.com/2073-4468/14/3/66
8. “FcRn Blockade as a Targeted Therapeutic Strategy in Antibody-Mediated Autoimmune Diseases: A Focus on Warm Autoimmune Hemolytic Anemia”
by Michael Sandhu and Irina Murakhovskaya
Antibodies 2025, 14(3), 65; https://doi.org/10.3390/antib14030065
Available online: https://www.mdpi.com/2073-4468/14/3/65
9. “Diagnosis of Systemic Rheumatic Disease Using the Connective Tissue Disease Screen”
by Abeline Kapuczinski†, Dorian Parisis†, Nour Kassab, Julie Smet and Muhammad Soyfoo
Antibodies 2025, 14(3), 56; https://doi.org/10.3390/antib14030056
Available online: https://www.mdpi.com/2073-4468/14/3/56
10. “Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies”
by Ge Yang and Mohammad Massumi
Antibodies 2025, 14(3), 52; https://doi.org/10.3390/antib14030052
Available online: https://www.mdpi.com/2073-4468/14/3/52
11. “Survival Outcomes and Prognostic Factors in Rheumatoid Arthritis Patients Receiving Biologic or Targeted Synthetic Therapy: Real-World Data”
by Zhaklin Apostolova, Tanya Shivacheva and Tsvetoslav Georgiev
Antibodies 2025, 14(3), 54; https://doi.org/10.3390/antib14030054
Available online: https://www.mdpi.com/2073-4468/14/3/54
12. “Clinical Characteristics, Comorbidities, and Treatment in Patients with Pemphigus—A Single-Center Retrospective Study”
by Natalia Welc, Sandra Ważniewicz†, Paweł Głuszak, Maciej Spałek, Agnieszka Seraszek-Jaros, Magdalena Jałowska and Marian Dmochowski
Antibodies 2024, 13(4), 103; https://doi.org/10.3390/antib13040103
Available online: https://www.mdpi.com/2073-4468/13/4/103
13. “Oral Paraneoplastic Pemphigus: A Scoping Review on Pathogenetic Mechanisms and Histo-Serological Profile”
by Domenico De Falco, Sabrina Messina and Massimo Petruzzi
Antibodies 2024, 13(4), 95; https://doi.org/10.3390/antib13040095
Available online: https://www.mdpi.com/2073-4468/13/4/95
14. “Limited Biomarker Potential for IgG Autoantibodies Reactive to Linear Epitopes in Systemic Lupus Erythematosus or Spondyloarthropathy”
by S. Janna Bashar, Zihao Zheng, Aisha M. Mergaert, Ryan R. Adyniec, Srishti Gupta, Maya F. Amjadi, Sara S. McCoy, Michael A. Newton and Miriam A. Shelef
Antibodies 2024, 13(4), 87; https://doi.org/10.3390/antib13040087
Available online: https://www.mdpi.com/2073-4468/13/4/87
15. “Intensity of Intrathecal Total IgG Synthesis in Multiple Sclerosis Correlates with the Degree of Pleocytosis, Diversity of Intrathecal Antiviral Antibody Specificities, and Female Sex”
by Benjamin Vlad, Marc Hilty, Stephan Neidhart, Klara Asplund Högelin, Mario Ziegler, Mohsen Khademi, Andreas Lutterotti, Axel Regeniter, Roland Martin, Faiez Al Nimer et al.
Antibodies 2024, 13(4), 102; https://doi.org/10.3390/antib13040102
Available online: https://www.mdpi.com/2073-4468/13/4/102